# Efficacy of Metformin in Preventing Diabetes in China

Study · id `cardio:ct-nct03441750` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03441750](<https://clinicaltrials.gov/study/NCT03441750>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT03441750

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1724 participants.

## Technical summary

Registry record NCT03441750. Randomized; no masking; primary purpose prevention. Start 2017-04-25 (actual); primary completion 2021-06-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 1724 participants (enrolled count; ClinicalTrials.gov record NCT03441750, source copy `cardio:ctgov-nct03441750-2021-11-15`, retrieved 2026-11-18)
- Started: 2017-04-25 (actual) (ClinicalTrials.gov record NCT03441750, source copy `cardio:ctgov-nct03441750-2021-11-15`, retrieved 2026-11-18)
- Primary completion: 2021-06-30 (actual) (ClinicalTrials.gov record NCT03441750, source copy `cardio:ctgov-nct03441750-2021-11-15`, retrieved 2026-11-18)
- Completion: 2021-06-30 (actual) (ClinicalTrials.gov record NCT03441750, source copy `cardio:ctgov-nct03441750-2021-11-15`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT03441750, source copy `cardio:ctgov-nct03441750-2021-11-15`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03441750-2021-11-15`, retrieved 2026-11-18)

## The registry's words

- Brief title: Efficacy of Metformin in Preventing Diabetes in China
- Acronym: ChinaDPP
- Condition: PreDiabetes
- Intervention (Drug): metformin
- Intervention (Other): Standard lifestyle intervention
- Lead sponsor: Chinese Association of Geriatric Research
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Prediabetes (`cardio:prediabetes`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial (`cardio:pubmed-37414069`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 735594025495590758577622fc4cef99fa7c7970517d9dc944a57f8db62e66c1
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
